Vimarsana
Biggest News Aggregation in the World

Tim Knotnerus News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Tim Knotnerus. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Tim Knotnerus Today - Breaking & Trending Today

Agomab Starts Phase 1 Clinical Study for AGMB-447 in Healthy Subjects and Patients with Idiopathic Pulmonary Fibrosis - Vimarsana News

Agomab Starts Phase 1 Clinical Study for AGMB-447 in Healthy Subjects and Patients with Idiopathic Pulmonary Fibrosis

Published: December 14, 2023

GHENT, Belgium, December 14, 2023--Agomab Therapeutics NV (‘Agomab’) today announced that it has dosed the first subject in a first-in-human Phase 1 clinical study of AGMB-447, an inhaled lung-restricted small molecule inhibitor of ALK5 (TGFβRI or ALK5). The study is evaluating AGMB-447 in healthy subjects and in patients with idiopathic pulmonary fibrosis (IPF).

Source: yahoo.com
Related Topics:
Gretchen SchweitzerTim KnotnerusTrophic CommunicationsAgomab TherapeuticsSingle Ascending DoseMultiple Ascending DoseChief Development OfficerIdiopathic Pulmonary FibrosisFibrostenosing CrohnIdiopathic PulmonaryTransforming Growth FactorHepatocyte Growth FactorStephanie MayLung TransplantLung DiseasesBusiness Wire
Belgian biotech company Agomab Therapeutics raises €94.9M to tackle fibrosis; here's how - Vimarsana News

Belgian biotech company Agomab Therapeutics raises €94.9M to tackle fibrosis; here's how

Published: October 11, 2023

Ghent, Belgium-based Agomab Therapeutics, a biotech company, announced on Wednesday that it has closed a $100M (approximately €94.9M).

Source: siliconcanals.com
Related Topics:
Felice Verduyn Van WeegenColleen CuffaroIyona RajkomarTim KnotnerusFidelity Management Research CompanyLife SciencesBelgium Based Agomab TherapeuticsFidelity ManagementResearch CompanyDawn BiopharmaFibrostenosing CrohnAgomab TherapeuticsIdiopathic Pulmonary FibrosisAdvancing Fibrosis FocusedChief Executive Officer
Agomab Raises $100M in Series C Funding - Vimarsana News

Agomab Raises $100M in Series C Funding

Published: October 11, 2023

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Source: finsmes.com
Related Topics:
Tim KnotnerusFidelity Management Research CompanyLife SciencesFidelity ManagementResearch CompanyDawn BiopharmaFibrostenosing Crohn
Agomab Therapeutics NV: Agomab Reports Positive Phase 1 Results with AGMB-129, a GI-restricted ALK5 Inhibitor for Fibrostenosing Crohn's Disease - Vimarsana News

Agomab Therapeutics NV: Agomab Reports Positive Phase 1 Results with AGMB-129, a GI-restricted ALK5 Inhibitor for Fibrostenosing Crohn's Disease

Published: February 2, 2023

-- All dosing regimens were well-tolerated across the Phase 1 clinical study -- -- High local exposure to AGMB-129 in the ileum -- -- No clinically relevant systemic exposure to AGMB-129, confirming

Source: finanznachrichten.de
Related Topics:
Eva MulderTim KnotnerusPhilippe WieselSchwierige ZeitenTrophic CommunicationsFibrostenosing CrohnChief Medical OfficerAgomab TherapeuticsStephanie May
Agomab Therapeutics Selected as One of Fierce Biotech's "Fierce 15" Companies of 2022 - Vimarsana News

Agomab Therapeutics Selected as One of Fierce Biotech's "Fierce 15" Companies of 2022

Published: September 12, 2022

Agomab Therapeutics Selected as One of Fierce Biotech's "Fierce 15" Companies of 2022 - read this article along with other careers information, tips and advice on BioSpace

Source: biospace.com
Related Topics:
Tim KnotnerusFierce BiotechChief Executive OfficerGomab Therapeutics Selected As One Of Fierce Biotech 39s Quot 15 Companies 2022